Seta Shahin

1.3k total citations · 1 hit paper
13 papers, 948 citations indexed

About

Seta Shahin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Seta Shahin has authored 13 papers receiving a total of 948 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 4 papers in Pulmonary and Respiratory Medicine and 3 papers in Genetics. Recurrent topics in Seta Shahin's work include Neutropenia and Cancer Infections (7 papers), Cancer Treatment and Pharmacology (3 papers) and Blood disorders and treatments (3 papers). Seta Shahin is often cited by papers focused on Neutropenia and Cancer Infections (7 papers), Cancer Treatment and Pharmacology (3 papers) and Blood disorders and treatments (3 papers). Seta Shahin collaborates with scholars based in United States, Australia and Italy. Seta Shahin's co-authors include John L. Marshall, David McCollum, Allen Lee Cohn, Edith P. Mitchell, Christopher Hagenstad, Philip J. Stella, Tarek Chidiac, Rafael G. Amado, J. Randolph Hecht and David R. Spigel and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and CHEST Journal.

In The Last Decade

Seta Shahin

13 papers receiving 916 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer

2008 644 citations J. Randolph Hecht, Edith P. Mitchell et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Seta Shahin United States	8	812	319	186	145	127	13	948
L. Leong United States	16	648 0.8×	241 0.8×	188 1.0×	144 1.0×	143 1.1×	41	1.0k
S. Palmeri Italy	17	584 0.7×	228 0.7×	91 0.5×	117 0.8×	116 0.9×	78	821
A. Misino Italy	11	755 0.9×	368 1.2×	221 1.2×	106 0.7×	134 1.1×	25	983
Nicola Borsellino Italy	10	707 0.9×	330 1.0×	226 1.2×	94 0.6×	81 0.6×	19	880
Lucio Giustini Italy	20	884 1.1×	407 1.3×	115 0.6×	294 2.0×	121 1.0×	41	1.3k
Swantje Held Germany	17	920 1.1×	444 1.4×	278 1.5×	318 2.2×	210 1.7×	85	1.1k
Mauro D’Amico Italy	10	1.0k 1.3×	414 1.3×	262 1.4×	284 2.0×	286 2.3×	32	1.2k
B. Nelson United States	7	795 1.0×	278 0.9×	199 1.1×	92 0.6×	84 0.7×	12	1.0k
Jaume Boadas Spain	16	570 0.7×	190 0.6×	436 2.3×	194 1.3×	236 1.9×	36	1.2k
Ralph Wong Canada	5	1.3k 1.6×	400 1.3×	199 1.1×	113 0.8×	325 2.6×	8	1.5k

Countries citing papers authored by Seta Shahin

Since Specialization

Citations

This map shows the geographic impact of Seta Shahin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Seta Shahin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Seta Shahin more than expected).

Fields of papers citing papers by Seta Shahin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Seta Shahin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Seta Shahin. The network helps show where Seta Shahin may publish in the future.

Co-authorship network of co-authors of Seta Shahin

This figure shows the co-authorship network connecting the top 25 collaborators of Seta Shahin. A scholar is included among the top collaborators of Seta Shahin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Seta Shahin. Seta Shahin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Nilsson, Mary, Brenda Crowe, Greg Anglin, et al.. (2020). Clinical Trial Drug Safety Assessment for Studies and Submissions Impacted by COVID-19. Statistics in Biopharmaceutical Research. 12(4). 498–505. 2 indexed citations

Roman, Lynda D., Cristina Saura, Irene Braña, et al.. (2019). Neratinib in patients with HER2-mutant, metastatic cervical cancer: findings from the phase 2 SUMMIT ‘basket’ trial. Gynecologic Oncology. 154. 11–11. 1 indexed citations

Ulaner, Gary A., Cristina Saura, Sarina A. Piha‐Paul, et al.. (2019). Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib. Clinical Cancer Research. 25(24). 7381–7387. 14 indexed citations

Zhou, Ying, Chunlei Ke, Qi Jiang, Seta Shahin, & Steven Snapinn. (2015). Choosing Appropriate Metrics to Evaluate Adverse Events in Safety Evaluation. Therapeutic Innovation & Regulatory Science. 49(3). 398–404. 12 indexed citations

Burris, Howard A., Chandra P. Belani, Peter A. Kaufman, et al.. (2010). Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non–Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: Results of Four Multicenter, Double-Blind, Randomized Phase II Studies. Journal of Oncology Practice. 6(3). 133–140. 74 indexed citations

Hecht, J. Randolph, Edith P. Mitchell, Tarek Chidiac, et al.. (2008). A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer. Journal of Clinical Oncology. 27(5). 672–680. 644 indexed citations breakdown →

Balducci, Lodovico, Veena Charu, Jennifer Tam, et al.. (2007). Elderly Cancer Patients Receiving Chemotherapy Benefit from First-Cycle Pegfilgrastim. The Oncologist. 12(12). 1416–1424. 98 indexed citations

Saven, Alan, L. Schwartzberg, Paul Kaywin, et al.. (2006). Randomized, double-blind, phase 2, study evaluating same-day vs next-day administration of pegfilgrastim with R-CHOP in non-Hodgkin’s lymphoma patients. Journal of Clinical Oncology. 24(18_suppl). 7570–7570. 16 indexed citations

Belani, Chandra P., S. Ramalingam, Anas Al-Janadi, et al.. (2006). A randomized double-blind phase II study to evaluate same-day vs next-day administration of pegfilgrastim with carboplatin and docetaxel in patients with NSCLC. Journal of Clinical Oncology. 24(18_suppl). 7110–7110. 7 indexed citations

10.

Crawford, Jeffrey, Michael Green, Brian McGuire, & Seta Shahin. (2005). A Combined Analysis of Average Relative Dose Intensity in the Chemotherapy of Solid Tumors with Pegfilgrastim or Filgrastim Support. PubMed. 2(4). 229–233. 2 indexed citations

11.

Balducci, Lodovico, et al.. (2005). A large study of the older cancer patient in the community setting: Initial report of a randomized controlled trial using pegfilgrastim to reduce neutropenic complications. Journal of Clinical Oncology. 23(16_suppl). 8111–8111. 5 indexed citations

12.

Kaufman, Peter A., et al.. (2004). Randomized double-blind phase 2 study evaluating sameday vs next-day administration of pegfilgrastim with docetaxel, doxorubicin, and cyclophosphamide (tac) in women with early stage and advanced breast cancer. Breast Cancer Research and Treatment. 88. 12 indexed citations

13.

Stoller, James K., Farshid N. Rouhani, Mark Brantly, et al.. (2002). Biochemical Efficacy and Safety of a New Pooled Human Plasma α1-Antitrypsin, Respitin. CHEST Journal. 122(1). 66–74. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact